Manish Chandey1, A S Multani. 1. Assistant Professor, Department of Medicine, Sri Guru Ram Das Institute of Medical Sciences and Research , Amritsar, Punjab, India.
Abstract
OBJECTIVE: To compare the efficacy and safety of azithromycin with ofloxacin in patients with uncomplicated typhoid fever. MATERIAL AND METHODS:Forty adult patients with bacteriologically or serologically diagnosed, uncomplicated typhoid fever were included from Medicine out-patient department at Government medical college, Amritsar, India. They were randomized into 2 groups of 20 patients each. Group I: patients received ofloxacin 200mg orally twice daily for 7 days. Group II: Patients received Azithromycin orally 1 gm on day 1 and then 500 mg daily from day 2 to day 6. The following parameters were noted a) fever clearance time b) cure rate c) adverse drug reaction d) recurrence of symptoms, if any, during 4 weeks follow up. RESULTS:Nineteen out of 20 patients from group I were cured with mean fever clearance time of 3.68 days while all 20 patients from group II were cured with mean fever clearance time of 3.65 days. No significant side effects were noted in any of the patients. No relapse was recorded in the present study in a follow up period of 4 weeks in both study groups. CONCLUSION: Both ofloxacin and Azithromycin are almost equally efficacious and safe in treatment of typhoid fever with no major adverse effect. Azithromycin is an effective alternative in conditions where ofloxacin is contraindicated i.e., children, pregnant women and quinolone resistant cases of typhoid fever.
RCT Entities:
OBJECTIVE: To compare the efficacy and safety of azithromycin with ofloxacin in patients with uncomplicated typhoid fever. MATERIAL AND METHODS: Forty adult patients with bacteriologically or serologically diagnosed, uncomplicated typhoid fever were included from Medicine out-patient department at Government medical college, Amritsar, India. They were randomized into 2 groups of 20 patients each. Group I: patients received ofloxacin 200mg orally twice daily for 7 days. Group II: Patients received Azithromycin orally 1 gm on day 1 and then 500 mg daily from day 2 to day 6. The following parameters were noted a) fever clearance time b) cure rate c) adverse drug reaction d) recurrence of symptoms, if any, during 4 weeks follow up. RESULTS: Nineteen out of 20 patients from group I were cured with mean fever clearance time of 3.68 days while all 20 patients from group II were cured with mean fever clearance time of 3.65 days. No significant side effects were noted in any of the patients. No relapse was recorded in the present study in a follow up period of 4 weeks in both study groups. CONCLUSION: Both ofloxacin and Azithromycin are almost equally efficacious and safe in treatment of typhoid fever with no major adverse effect. Azithromycin is an effective alternative in conditions where ofloxacin is contraindicated i.e., children, pregnant women and quinolone resistant cases of typhoid fever.
Authors: D B Bethell; N P Day; N M Dung; C McMullin; H T Loan; D T Tam; L T Minh; N T Linh; N Q Dung; H Vinh; A P MacGowan; L O White; N J White Journal: Antimicrob Agents Chemother Date: 1996-09 Impact factor: 5.191
Authors: N I Girgis; T Butler; R W Frenck; Y Sultan; F M Brown; D Tribble; R Khakhria Journal: Antimicrob Agents Chemother Date: 1999-06 Impact factor: 5.191
Authors: John A Crump; Katrina Kretsinger; Kathryn Gay; R Michael Hoekstra; Duc J Vugia; Sharon Hurd; Susan D Segler; Melanie Megginson; L Jeffrey Luedeman; Beletshachew Shiferaw; Samir S Hanna; Kevin W Joyce; Eric D Mintz; Frederick J Angulo Journal: Antimicrob Agents Chemother Date: 2008-01-22 Impact factor: 5.191
Authors: Tran Thuy Chau; James Ian Campbell; Claudia M Galindo; Nguyen Van Minh Hoang; To Song Diep; Tran Thu Thi Nga; Nguyen Van Vinh Chau; Phung Quoc Tuan; Anne Laure Page; R Leon Ochiai; Constance Schultsz; John Wain; Zulfiqar A Bhutta; Christopher M Parry; Sujit K Bhattacharya; Shanta Dutta; Magdarina Agtini; Baiqing Dong; Yang Honghui; Dang Duc Anh; Do Gia Canh; Aliya Naheed; M John Albert; Rattanaphone Phetsouvanh; Paul N Newton; Buddha Basnyat; Amit Arjyal; Tran Thi Phi La; Nguyen Ngoc Rang; Le Thi Phuong; Phan Van Be Bay; Lorenz von Seidlein; Gordon Dougan; John D Clemens; Ha Vinh; Tran Tinh Hien; Nguyen Tran Chinh; Camilo J Acosta; Jeremy Farrar; Christiane Dolecek Journal: Antimicrob Agents Chemother Date: 2007-10-01 Impact factor: 5.191
Authors: Christopher M Parry; Ha Vinh; Nguyen Tran Chinh; John Wain; James I Campbell; Tran Tinh Hien; Jeremy J Farrar; Stephen Baker Journal: PLoS Negl Trop Dis Date: 2011-06-21
Authors: Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar Journal: Cochrane Database Syst Rev Date: 2019-01-18
Authors: Farhana Khanam; Nazmul Hasan Rajib; Susan Tonks; Md Khalequzzaman; Andrew J Pollard; John D Clemens; Firdausi Qadri Journal: Am J Trop Med Hyg Date: 2020-05-21 Impact factor: 2.345
Authors: Celina Jin; Malick M Gibani; Shaun H Pennington; Xinxue Liu; Alison Ardrey; Ghaith Aljayyoussi; Maria Moore; Brian Angus; Christopher M Parry; Giancarlo A Biagini; Nicholas A Feasey; Andrew J Pollard Journal: PLoS Negl Trop Dis Date: 2019-12-26